<DOC>
	<DOCNO>NCT02311179</DOCNO>
	<brief_summary>This study focus effect hydroxyapatite coating BoneMaster fixation hip prosthesis primary hip alloplasty . A hemispheric joint cup type Exceed cup ( Biomet ) characterize porous surface titanium plasma spray use . The surface coat hydroxyapatite deposit electrochemically ( BoneMaster ) compare identical cup without hydroxyapatite .</brief_summary>
	<brief_title>The Effect Implant Coating ( BoneMaster ) Migration Clinical Outcome Hip Arthoplasty With Exceed Cup</brief_title>
	<detailed_description>This study focus effect hydroxyapatite coating BoneMaster fixation hip prosthesis primary hip alloplasty . A hemispheric joint cup type Exceed cup ( Biomet ) characterize porous surface titanium plasma spray use . The surface coat hydroxyapatite deposit electrochemically ( BoneMaster ) compare identical cup without hydroxyapatite . A 5-year radiologic analysis migration carry object detect prognostic evidence prosthesis loosening . Migration determine Roentgen Stereo-photogrammetric Analysis ( RSA ) stereoroentgenograms . Simultaneously , patient monitor use clinical outcome measure HOOS ( Hip disability osteoarthritis outcome score ) , OHS ( Oxford Hip Score ) , EQ-5D ( EuroQol ) , HHS ( Harris Hip Score ) range motion , VAS ( Visual Analog Scale ) , postoperative complication reoperation . Hypothesis : We expect Exceed cup hydroxyapatite deposit electrochemically ( BoneMaster ) superior equal compare similar cup without hydroxyapatite regard - mechanical stability ( RSA ) - ( clinical outcome )</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Cimetidine</mesh_term>
	<criteria>1 . Symptomatic radiographic osteoarthritis 2 . Radiographically clinically adequate bone quality regard total hip prosthesis , include osteoporosisDexaScanning verification . 3 . Age 55 75 year 4 . Informed write consent Orthopaedic 1 . Other disease affect hip primary coxarthrosis time inclusion 1.1 . Secondary osteoarthritis 1.1.1. sequela acetabular fracture 1.1.2. hipnear femoral fracture 1.1.3. calve perthe 1.1.4. dysplasia ( severe ) 1.1.5. 1.2 Atraumatic caput necrosis 2 . Neuromuscular vascular condition one low extremity 3 . Immobilization postoperative long period , instance serious disease , alloplasties lowerextremity joint , etc ( decided investigator ) 4 . Reoperation affect hip 4.1 luxation ( closed open reduction ) 4.2 deep infection 4.3 fracture 4.4 aseptic loosen 4.5 5 . Body Mass Index ( BMI ) time inclusion 8184 5.1 â‰¥ 35 kg/m2 ( grade 2+3 85 , Obese Class I 81 ) 5.2 &lt; 18,5 kg/m2 8184 6 . Insufficient RSA marker spread rigidity Operative 7 . Use component Bimetric femoral stem ( HA porouscoated without collar ) 8 . Unsuitable bone quality uncemented hip alloplasty , evaluate preoperatively 9 . Complications peroperatively insertion hip alloplasty necessitate deviation describe operative procedure ( see section : `` Operative procedure '' ) , among others 9.1 per postoperative fracture 9.2 bone graft use peroperatively ( treatment bone defect , cyst , etc . ) 9.3 screw fixation acetabulum 9.4 gluteal detachment extensive femoral exposure 9.5 trochanter osteotomy 9.6 Underreamning 12 mm ( cup size one mm large reamer , i.e . reamning 51 mm , cup 52 mm ) 9.7 Other Radiographic 10 . Cup placement 10.1 Cup inclination AP plan &gt; 56 degree &lt; 35 degree evaluate roentgenogram Medical 11 . Osteoporosis 11.1. previosly diagnose 11.2. projectrelated preoperative DEXA scan Patients osteoporosis scan ( Tscore &lt; 2.5 ) exclude study referral medical osteoporosis treatment . Patients osteopenia ( Tscore &lt; 1 ) include project referral osteoporosis prophylactic treatment . Patients osteopenia project inclusion DEXA rescanned 2 year follow . 12 . Arthritis 12.1. rheumatoid arthritis 12.2. psoriasis arthritis 12.3. arthritides 13 . Metabolic bone disease 13.1. hyperparathyroidism 13.2 . Paget bone disease 13.3. renal osteodystrophy 13.4. 14 . Reduced kidney function thereby influence bone metabolism 15 . Previous treatment skeleton radiation therapy 16 . Cancer Pharmaceuticals 17 . Pharmaceuticals effect calciumphosphorus metabolism bone density 8798 , either intermittent administration constant dose 17.1. glucocorticoid ( systemic ) beyond shortterm treatment ( &lt; 5 day ) 17.2. immunosuppression/modulation ( cyclosporine , methotrexate , etc . ) Compliance related 18 . Absent patient compliance treatment followup investigation 19 . Abuse investigator feel would weaken compliance 19.1. alcohol abuse 19.2. medication abuse 20 . Psychological instability ( include patient treatment lithium/antidepressants/neuroleptics/ antipsychotic drug ) investigator feel would weaken compliance</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Prosthesis fixation</keyword>
	<keyword>hip arthroplasty</keyword>
</DOC>